Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Itoh-Nakadai A, Liang M, Shindo M, Bibi C, Tomizawa-Murasawa M, Fujiki S, Kaneko A, Kanamaru E, Hashimoto M, Kajita H, Ando Y, Kojima M, Moody J, Iwasaki M, Takagi S, Nakagawa R, Agrawal S, Amitani-Iijima H, Sato K, Sorimachi Y, Suzuki N, Fukami T, Hanada K, Morita S, Katsura K, Matsumoto T, Kobayashi M, Kato M, Negishi Y, Shirouzu M, Najima Y, Takubo K, Hon CC, Uchida N, Taniguchi S, Momozawa Y, Carninci P, Shultz LD, Saito Y, de Hoon M, Shin JW, Ishikawa F. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat Commun. 2026 Jan 26; 17(1):101.
-
Kim J, Shin DW, Lee J, Lee MJ, Yu YG, Lee DH, Kang TH. Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer. ACS Synth Biol. 2026 Jan 16; 15(1):309-320.
-
Qiu J, Alp Y, Gong S, Szipszky P, Jerry DJ, Thayumanavan S. HER2 Antibody-Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody-Drug Conjugates. Nano Lett. 2026 01 14; 26(1):246-253.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13; 13(3).
-
Banday S, Mishra AK, Rashid R, Ye T, Ali A, Li J, Yustein JT, Kelliher MA, Zhu LJ, Deibler SK, Malonia SK, Green MR. The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma. Nat Commun. 2025 Feb 02; 16(1):1267.
-
Raman V, Hall CL, Wetherby VE, Whitney SA, Van Dessel N, Forbes NS. Controlling intracellular protein delivery, tumor colonization and tissue distribution using flhDC in clinically relevant ?sseJ Salmonella. Mol Ther. 2025 Feb 05; 33(2):649-669.
-
Rozen EJ, Frantz W, Wigglesworth K, Vessella T, Zhou HS, Shohet JM. Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis. Mol Cancer Ther. 2024 Aug 01; 23(8):1124-1138.
-
Sicinska E, Kola VSR, Kerfoot JA, Taddei ML, Al-Ibraheemi A, Hsieh YH, Church AJ, Landesman-Bollag E, Landesman Y, Hemming ML. ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer Res. 2024 Jul 15; 84(14):2247-2264.
-
Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A, Huuhtanen J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP, Kim WS, Choi J, Roels J, Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S. KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes. Clin Cancer Res. 2024 Jun 03; 30(11):2514-2530.